ATX
AMPLIA FPO [ATX]
Healthcare · ASX Small Cap
$0.2620 +0.8%
Updated 26 Mar 2026 · Scores refresh every scan
Score Breakdown
Technical86
Catalyst39
Sentiment50
Fundamental64
Momentum82
Risk Gate47
Get alerts when ATX's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- MACD momentum is picking up steam
- Pressing against the upper Bollinger Band — extended and may need to cool off
- Trading above both moving averages — the trend is your friend here
- Volume surging at 55.0x normal while price climbs — real buying conviction behind this move
- Just broke above 20-day resistance — a level that was capping price, now cleared
- On a tear — up 132.9% over the last 5 days
- Beating the Small Ords index — relative strength of 2.44, so it's outpacing the pack
- Volatility is expanding fast — choppy price action, so buckle up
- Trading above the 200-day average — the long-term trend is on your side
- Strong cash runway (9 quarters)
- Strong revenue growth (+87%)
- EPS estimates revised downward (-6pts)
- CANSLIM I: Institutional ownership (19%)
- Sentiment is mixed — no strong consensus either way
- Strong long-term momentum — up 140% over the past year (excluding last month)
- Excellent risk-adjusted returns — Sharpe of 1.5 means strong gains without wild swings
- Revenue growing at +87% — the top line is moving in the right direction
- The bigger volume days are the up days — volume-weighted momentum is positive (44.81%/day)
- RBA hiking (-3pts)
- Trial readout: PHASE1 (est. 2026-05-01)
Risk Signals
- RSI is running hot — overbought territory, so expect some pullback risk
- Stochastic is stretched into overbought — could need a breather
- RSI is overbought but volume confirms it — this could be genuine momentum, not just froth
- Deeply negative margins (-158%)
- Not enough chatter to gauge sentiment — defaulting to neutral
- Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about ATX
3 free messages/day · Unlimited with Pro
Recent Catalysts
NONE Amplia Reports Improved Responses & Survival in ACCENT trial
NONE Pause in Trading
NONE Benefit of Narmafotinib in kRas-Mutated Cancer Models
NEGATIVE Trading Halt
Recent ASX Announcements
| 2026-03-22 | Amplia Reports Improved Responses & Survival in ACCENT trial PRICE SENSITIVE |
| 2026-03-18 | Trading Halt PRICE SENSITIVE |
| 2026-03-18 | Pause in Trading PRICE SENSITIVE |
| 2026-03-08 | Benefit of Narmafotinib in kRas-Mutated Cancer Models |
| 2026-02-24 | Appointment of Chief Financial Officer |
Key Metrics
$107.7M
Market Cap
5.7M
Avg Volume
55.0x
Vol Ratio
$0.05 — $0.42
52-Week Range
0.0%
Short Interest
N/A
Cash Runway
-28.5%
ROE
-158.5%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 85% |
| L | Leader vs Laggard | pass | RS: 17 |
| I | Institutional Sponsorship | pass | Inst: 19% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
Ranked #1 of 117 · Sector avg: 46
View all Healthcare signals →Track ATX and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.
No credit card required